Osprey Pharmaceuticals USA (OPUS) is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases. The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases. The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy. The company has developed a powerful chemokine-based protein therapeutic platform based on our pioneering insight into the chemokine system, a complex network of chemokine molecules (ligands) and receptors that regulate cell migration and inflammatory immune responses. Each of our novel protein therapeutics is designed to target a specific chemokine receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.